COMPANY

DalCor Pharmaceuticals

HQ: Sarasota, FL (US office) source · dalcorpharma.com ↗

DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. From company website Source · Oct 13, 2026

Keywords: biopharmaceutical pharmaceuticals cardiovascular Acute Coronary Syndrome Covid19

Location: Sarasota, FL (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $6.96M (Form D filed Aug 28, 2026). SEC Form D 0001231919-26-001113 (Aug 28, 2026)
Evidence (1 event)
- Aug 28, 2026 · SEC Form D 0001231919-26-001113
  Name of Issuer: DalCor Pharmaceuticals US, LLC; CIK: 1673368; Address: Sarasota, FL; Submission type: D; Filing date: 2026-08-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6958236; Total Amount Sold: 6958236; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Oct 3, 2023 Trial start Phase 3: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS source ↗
Jan 11, 2021 Trial start Phase 2: Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 source ↗
2016-04 Trial start Phase 3: Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS source ↗

Upcoming milestones

2027-08 (ESTIMATED) · Phase 3 · Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS · NCT05918861

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05918861	Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Phase 3	Recruiting	Oct 3, 2023	2027-08 (estimated)
NCT04676867	Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19	Phase 2	Completed	Jan 11, 2021	May 17, 2021 (actual)
NCT02525939	Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS	Phase 3	Completed	2016-04	2021-10 (actual)